Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07384767 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing
A Phase 2 study, sponsored by University of California, Davis.
- Not yet
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT07384767 is a Phase 2 study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 220 participants.
The verdict
NCT07384767, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\&C). Please note that healing by secondary intention refers to when a wound heals naturally without surgical closure. To evaluate the efficacy of topical timolol 0.5%, 220 participants will be recruited. Participants will be placed into one of two groups: The treatment group or the control group. 1. The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks. 2. The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks. During this 12-week period, both groups will be required to upload photos of their wound healing to their MyChart account at weeks 3, 6, 9, and 12. These photos will be reviewed by the investigator to assess wound healing. Re-epithelialization and earlier complete wound healing will be compared between both groups to determine the efficacy of topical timolol 0.5% solution compared to the standard of care.
Interventions
- DRUG Timolol 0.5% Ophthalmic Solution
- OTHER Hydrogel of placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07384767
The ClinicalTrials.gov registry entry for NCT07384767 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Timolol 0.5% Ophthalmic Solution is the first listed.
NCT07384767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07384767 about?
NCT07384767 is a clinical study titled "Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing". The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\&C). Please note that healing by secondary intenti...
What is the current status of trial NCT07384767?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2026-06-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07384767?
The interventions under investigation include: Timolol 0.5% Ophthalmic Solution (DRUG), Hydrogel of placebo (OTHER).
Who is sponsoring clinical trial NCT07384767?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.